National Cancer Control Programme Technology Review Committee
Terms of Reference

Version 6
29/11/2022

The National Cancer Control Programme (NCCP) Technology Review Committee (TRC) is responsible for reviewing proposals received from industry or expert groups in Ireland for funding of new products[1] for cancer, or expanded indications for existing products or related predictive laboratory tests for cancer. This include medicines being assessed for reimbursement via the standard HSE assessment processes.

The Committee reports to the Director of the NCCP. The Committee will make a recommendation in relation to funding and availability of a new treatment or test for consideration by the relevant body e.g., HSE drugs group.

The recommendations will be based on the degree of unmet clinical need, clinical effectiveness, alternative therapies available, toxicity (where relevant) and the cost effectiveness of the proposed technology[2]. The recommendations will be informed by the Committee discussion, guidelines developed by the relevant clinical group and the critique of the Health Technology Assessment submission, or similar, by the National Centre for Pharmacoeconomics (NCPE) or other body. It is noted that NCPE summary reports are published on the NCPE website and patient organisations/patients may make submissions to NCPE.

Members of the Committee, observers and invited experts must keep all discussions and commercial information confidential.

Recommendations* to the NCCP Director will be communicated by the NCCP Director to the HSE Drugs Group, in the case of medicines, or other relevant HSE Group in the case of tests or other technologies, for potential funding and implementation planning.

Chairman:

- Chair: appointed by the NCCP Director

Members:

1. A minimum of three members recommended by relevant professional society, faculty or college, who have content experience in the specific discipline and are approved by the NCCP Director (e.g. Medical Oncology, Haemato-Oncology)

[1] Product is defined for this purpose as an item that requires product/marketing authorisation from a regulatory body.
[2] As defined in the Health Act 2013
* The committee will provide an indicative recommendation in relation to each technology considered, indicating in each case whether the technology is:
- Recommended
- Not recommended
- Recommended pending an improved business impact following discussion with company required
- Additional information required from company
- Other (to be defined in relation to the specific technology considered)

2. NCCP Chief Pharmacist (Cancer Drug Management Programme)
3. A minimum of one member with Health Economical, Pharmacoeconomics or statistics and epidemiology expertise
4. One representative appointed by HIQA.
5. Primary Care Eligibility and Reimbursement Services representative.
6. Up to three additional members may be appointed.

Alternate members may be nominated as replacement for members to ensure quorum can be met.

Term of appointment of members:
Membership will be reviewed every three years, including by the nominating bodies.

Attendance:
Non-attendance at three consecutive meetings may lead to removal from the membership of the Committee and the appointment of a replacement.

Observers:

- NCCP Director
- NCCP National Medical Oncology Programme Clinical Advisor
- NCCP National Clinical Lead for Haemato-oncology
- NCCP Systemic Therapy Programme representative/s as appropriate.

Invited Experts
Experts in a particular area, e.g. pathology or radiology who are not members of the committee, may be invited to attend specific meetings or for specific items at a meeting, as appropriate.

Quorum:

At least five members, including a minimum of three clinicians from membership grouping 1 (see list above).

Secretariat
The secretariat to the Committee is provided by NCCP.

Requirements of Chairman, members, observers & invited experts

- The Chairman and members and must complete a conflict of interest declaration annually. Invited experts may be required to complete a conflict of interest declaration.

- Members, or invited experts with a conflict of interest with regard to a particular technology should declare the conflict to the committee, or to the committee chair. The member / invited expert may choose to withdraw from discussion of specific item, or withdraw at the request of the committee, or the chair.